Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications

O. Nicolatou-Galitis; M. Migkou; A. Psyrri; A. Bamias; D. Pectasidis; T. Economopoulos; J.E. Raber-Durlacher; G. Dimitriadis; M.A. Dimopoulos

doi:10.1016/j.tripleo.2011.08.024

Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications

O. Nicolatou-Galitis, M. Migkou, A. Psyrri, A. Bamias, D. Pectasidis, T. Economopoulos, J.E. Raber-Durlacher, G. Dimitriadis, M.A. Dimopoulos

Periodontology

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

There is emerging evidence that oral mucositis/stomatitis is a common adverse effect of sunitininb antiangiogenic therapy in patients with metastatic renal cell carcinoma (mRCC). In addition, a case of sunitinib-related jaw osteonecrosis was recently described. We report on 2 patients with mRCC treated with sunitinib. The first patient, a 19-year-old woman, treated with cisplatin and sunitinib, presented with oral pain, malodor, spontaneous and continuous gingival bleeding, and
painful necrotic ulcerations clinically resembling necrotizing ulcerative gingivitis (NUG). Suntinib-related stomatitis and bleeding were considered cumulative to NUG symptoms. The second patient, a 64-year-old woman, treated with sunitinib only, complained of mandibular pain. Sunitinib-related jaw osteonecrosis was diagnosed. Gingival bleeding and soft tissue necrosis, as well as jaw osteonecrosis may develop as adverse events of sunitinib use. Antiangiogenic therapies are
increasingly used in the treatment of cancers. The presented cases are aimed to alert health care professionals on adverse oral events.

Original language	English
Pages (from-to)	234-238
Journal	Oral surgery oral medicine oral pathology oral radiology
Volume	113
Issue number	2
DOIs	https://doi.org/10.1016/j.tripleo.2011.08.024
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tripleo.2011.08.024

Persistent URL (handle)

Persistent link

Cite this

Nicolatou-Galitis, O., Migkou, M., Psyrri, A., Bamias, A., Pectasidis, D., Economopoulos, T., Raber-Durlacher, J. E., Dimitriadis, G., & Dimopoulos, M. A. (2012). Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral surgery oral medicine oral pathology oral radiology, 113(2), 234-238. https://doi.org/10.1016/j.tripleo.2011.08.024

@article{9ceabfee0dba43ed8ee2fb3eae302fae,

title = "Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications",

abstract = "There is emerging evidence that oral mucositis/stomatitis is a common adverse effect of sunitininb antiangiogenic therapy in patients with metastatic renal cell carcinoma (mRCC). In addition, a case of sunitinib-related jaw osteonecrosis was recently described. We report on 2 patients with mRCC treated with sunitinib. The first patient, a 19-year-old woman, treated with cisplatin and sunitinib, presented with oral pain, malodor, spontaneous and continuous gingival bleeding, and painful necrotic ulcerations clinically resembling necrotizing ulcerative gingivitis (NUG). Suntinib-related stomatitis and bleeding were considered cumulative to NUG symptoms. The second patient, a 64-year-old woman, treated with sunitinib only, complained of mandibular pain. Sunitinib-related jaw osteonecrosis was diagnosed. Gingival bleeding and soft tissue necrosis, as well as jaw osteonecrosis may develop as adverse events of sunitinib use. Antiangiogenic therapies areincreasingly used in the treatment of cancers. The presented cases are aimed to alert health care professionals on adverse oral events.",

author = "O. Nicolatou-Galitis and M. Migkou and A. Psyrri and A. Bamias and D. Pectasidis and T. Economopoulos and J.E. Raber-Durlacher and G. Dimitriadis and M.A. Dimopoulos",

year = "2012",

doi = "10.1016/j.tripleo.2011.08.024",

language = "English",

volume = "113",

pages = "234--238",

journal = "Oral surgery oral medicine oral pathology oral radiology",

issn = "2212-4403",

publisher = "Elsevier Inc.",

number = "2",

}

Nicolatou-Galitis, O, Migkou, M, Psyrri, A, Bamias, A, Pectasidis, D, Economopoulos, T, Raber-Durlacher, JE, Dimitriadis, G & Dimopoulos, MA 2012, 'Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications', Oral surgery oral medicine oral pathology oral radiology, vol. 113, no. 2, pp. 234-238. https://doi.org/10.1016/j.tripleo.2011.08.024

Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. / Nicolatou-Galitis, O.; Migkou, M.; Psyrri, A. et al.
In: Oral surgery oral medicine oral pathology oral radiology, Vol. 113, No. 2, 2012, p. 234-238.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications

AU - Nicolatou-Galitis, O.

AU - Migkou, M.

AU - Psyrri, A.

AU - Bamias, A.

AU - Pectasidis, D.

AU - Economopoulos, T.

AU - Raber-Durlacher, J.E.

AU - Dimitriadis, G.

AU - Dimopoulos, M.A.

PY - 2012

Y1 - 2012

N2 - There is emerging evidence that oral mucositis/stomatitis is a common adverse effect of sunitininb antiangiogenic therapy in patients with metastatic renal cell carcinoma (mRCC). In addition, a case of sunitinib-related jaw osteonecrosis was recently described. We report on 2 patients with mRCC treated with sunitinib. The first patient, a 19-year-old woman, treated with cisplatin and sunitinib, presented with oral pain, malodor, spontaneous and continuous gingival bleeding, and painful necrotic ulcerations clinically resembling necrotizing ulcerative gingivitis (NUG). Suntinib-related stomatitis and bleeding were considered cumulative to NUG symptoms. The second patient, a 64-year-old woman, treated with sunitinib only, complained of mandibular pain. Sunitinib-related jaw osteonecrosis was diagnosed. Gingival bleeding and soft tissue necrosis, as well as jaw osteonecrosis may develop as adverse events of sunitinib use. Antiangiogenic therapies areincreasingly used in the treatment of cancers. The presented cases are aimed to alert health care professionals on adverse oral events.

AB - There is emerging evidence that oral mucositis/stomatitis is a common adverse effect of sunitininb antiangiogenic therapy in patients with metastatic renal cell carcinoma (mRCC). In addition, a case of sunitinib-related jaw osteonecrosis was recently described. We report on 2 patients with mRCC treated with sunitinib. The first patient, a 19-year-old woman, treated with cisplatin and sunitinib, presented with oral pain, malodor, spontaneous and continuous gingival bleeding, and painful necrotic ulcerations clinically resembling necrotizing ulcerative gingivitis (NUG). Suntinib-related stomatitis and bleeding were considered cumulative to NUG symptoms. The second patient, a 64-year-old woman, treated with sunitinib only, complained of mandibular pain. Sunitinib-related jaw osteonecrosis was diagnosed. Gingival bleeding and soft tissue necrosis, as well as jaw osteonecrosis may develop as adverse events of sunitinib use. Antiangiogenic therapies areincreasingly used in the treatment of cancers. The presented cases are aimed to alert health care professionals on adverse oral events.

U2 - 10.1016/j.tripleo.2011.08.024

DO - 10.1016/j.tripleo.2011.08.024

M3 - Article

SN - 2212-4403

VL - 113

SP - 234

EP - 238

JO - Oral surgery oral medicine oral pathology oral radiology

JF - Oral surgery oral medicine oral pathology oral radiology

IS - 2

ER -

Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this